Scientific Online Resource System

Annual for Hospital Pharmacy

Negative Opinion Of The EMA – Overview On Marketing Authorization Procedures Concluded With Rejection In 2018-2019

Violeta Getova


Every year the European medicines agency assesses numerous applications for marketing authorization of new medicines. A part of them are rejected most often due to lack of sufficient efficacy data or unacceptable safety profile. For the period 2018-2019 around 5% of the marketing authorization applications via centralized procedure were rejected, including some which do not have approved therapeutic alternatives at the moment. The current study aims at pointing out the priorities EMA follows in the assessment of data and to analyze the reasons which led to rejection of the marketing authorization applications.


marketing authorization, centralized procedure, quality, efficacy, safety

Full Text


Stoimenova A, B Kirilov, St. Gueorguiev, E. Petkova-Gueorguieva, S. Ognianov. Good Manufacturing Practice for Medicinal Products in Bulgaria: an Analysis of Regulatory Inspection Findings. Folia medica. March 2020; 62 (1): 165-171.

Петрова Г. и кол., Социална фармация и фармацевтично законодателство, Инфофарма, 2017

Гетов И, Е. Насева, Х. Лебанова, Е. Григоров. Основи на фармакоепидемиологията. МУ-София, ЕкоПринт, София, 2013 г., с.203. ISBN 978-954-92284-9-6

Ghalamkarpour A., Marketing authorization procedures in the European Union – making the right choice, Life science, 33/December 2009

From laboratory to patient: the journey of a medicine assessed by EMA, EMA/103813/2018 Rev. 1, 2019;

Human medicines highlights 2018, EMA/790649/2018, 2018;

Reflection paper on chemical structure and properties criteria to be considered for the evaluation of new active substance status of chemical substances, EMA/CHMP/QWP/104223/2015, 17 December 2015;

Assessment report Encyzix, EMA/88321/2018, 25 January 2018;

Assessment report Dexxience, EMA/548301/2018, 26 July 2018;

Assessment report Eladynos, EMA/CHMP/581111/2018, 26 July 2018;

Assessment report Alsitek, EMA/406203/2018, 18 April 2018;

Assessment report Exondys, EMA/691796/2018, 20 September 2018;

Human medicines highlights 2019,

Questions and answers on generic medicines, EMA/393905/2006 Rev. 2, 22 November 2012,

Assessment report Cabazitaxel Teva, EMA/280661/2019, 26 April 2019,

Assessment report Doxolipad, EMA/398153/2019, 29 May 2019,

Refusal of marketing authorization for Hopveus, EMA/232257/2020, EMEA/H/C/004962, 30 April 2020,

Assessment report Vanflyta, EMA/CHMP/602286/2019, 17 October 2019,



Article Tools
Email this article (Login required)